Chromatography, AffinityDEAD-box RNA HelicasesDNA
Dr. Steven Alan Akman, MD
NPI1396729414PAC ID9739224379
- Medicare services, 2024
- 437
- Medicare patients, 2024
- 116
- Part D claims, 2024
- 549
- Publications
- 17
- Clinical trials
- 10
- Practice address
- 1208 2 Island Ct, Mount Pleasant, SC 29466
- Practice phone
- Call (803) 286-4666
- Professional email
- Get professional email
- Personal email
- Get personal email
- Mobile number
- Get mobile number
Primary practice
MUSC Physicians
Mount Pleasant, South Carolina
Find Dr. Akman's professional email, personal email and mobile number
Dmand AI checks each channel through healthcare-specific waterfall enrichment. See what is on file with a free account, with practice phones, licenses and affiliations.
Dr. Steven Alan Akman is a hematologist and oncologist in Mount Pleasant, South Carolina
Dr. Akman practices at MUSC Physicians in Mount Pleasant, South Carolina.
Dr. Akman's NPI, 1396729414, was assigned on December 1, 2005. Dr. Akman graduated from Albert Einstein College of Medicine of Yeshiva University in 1975. Dr. Akman holds South Carolina license 35266.
NPI and contact details
- NPI
- 1396729414NPI Registry (opens in a new tab)
- Medicare PAC ID
- 9739224379
- NPI enumeration date
- December 1, 2005
- NPI status
- Active
- Accepts Medicare assignment
- Yes
- Offers telehealth
- Yes
- Practice phone
- (803) 286-4666
- Professional email
- Get email
- Personal email
- Get email
- Mobile number
- Get number
- Sex
- Male
- Estimated age
- 77
- Medical school graduation
- 1975
Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; Dmand AI Practice Data; and Doctors and Clinicians National Downloadable File (CMS)
Dr. Steven Alan Akman practices at MUSC Physicians in Mount Pleasant, South Carolina
Dr. Akman's primary practice is MUSC Physicians, at 1208 2 Island Ct, Mount Pleasant, SC 29466 in Charleston County. The practice phone is (803) 286-4666.
- MUSC Physicians1208 2 Island Ct, Mount Pleasant, SC 29466 · Charleston CountyPhone(803) 286-4666
Sources: NPPES NPI Registry (CMS); and Dmand AI Practice Data
Dr. Steven Alan Akman is affiliated with 8 sites of care and 6 medical groups
Dr. Akman's primary practice is MUSC Physicians in Mount Pleasant, South Carolina. Dr. Akman is also affiliated with MUSC Health University Medical Center. The medical group on file is MUSC Health. Dmand AI also links Dr. Akman to 2 more hospitals, 5 medical groups, 3 group practices and clinics and 1 home health agency, each named with a free account.
MUSC PhysiciansPrimary
Sources: NPPES NPI Registry (CMS); Dmand AI Practice Data; and Dmand AI Affiliation Data
Dmand AI tracks the EHR system at Dr. Steven Alan Akman's practice
Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Akman practices, 7 sites in all. Vendor and product names are available with a free account.
| Site | EHR vendor and product |
|---|---|
| MUSC Physicians | Available with a free account |
| +7 more sites and 5 medical groups | Available with a free account |
Source: Dmand AI Technology Install Data
For health IT teams
See the EHR and IT leaders at every site where Dr. Akman practices
Dmand AI maps EHR vendors, IT decision makers and buying committees across each health system and 6.2K+ hospitals, with verified contacts in the same login.
Dr. Steven Alan Akman is one of 157 hematologists and oncologists in South Carolina
Hematology and oncology is Dr. Akman's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Akman's licenses on file in 2 states: South Carolina and North Carolina.
Specialties and state licenses
- Hematology and oncology, South CarolinaPrimary
- North Carolina license
Hematologists and oncologists near Dr. Akman
Counts of hematologists and oncologists with a Dmand AI profile, by place and practice. Each opens the list.
157hematologists and oncologists in South Carolina
5hematologists and oncologists in Mount Pleasant
Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; and Dmand AI Peer Benchmarks
Dr. Steven Alan Akman billed Medicare for 437 services in 2024
CMS data shows 437 Medicare services from Dr. Akman across 4 procedure codes in 2024, for 116 Medicare patients. Medicare paid $23,115 for them.
Medicare services, 2024437
Medicare patients116
Paid by Medicare$23,115
Procedure codes4
Dr. Akman's Medicare services by type, 2023 to 2024
- 2023
- 2024
- Office and hospital visits
- 2023: 2342024: 2413%
- Other services
- 2023: 02024: 196
Where Dr. Akman's Medicare services took place, 2024
- In an office21950%
- In a facility21850%
Dr. Akman compared with the South Carolina median for hematologists and oncologists, 2024
- Dr. Akman
- South Carolina median
- Medicare services
- 437vs 1,53472% below
- Medicare patients
- 116vs 38970% below
- Part D claims
- 296vs 68657% below
Medians across 160 hematologists and oncologists in South Carolina with Dmand AI profiles that report each measure.
Dr. Akman's most billed Medicare procedure codes, 2024
CMS publishes codes billed for 11 or more Medicare patients. Each label is the code family; CPT descriptions are licensed by the AMA.
Need commercial claims for Dr. Akman?
Medicare shows one payer. Book a meeting to get commercial claims data for Dr. Akman and other hematologists and oncologists in South Carolina.
Sources: Medicare Physician & Other Practitioners - by Provider and Service (CMS), 2024 data; and Dmand AI Peer Benchmarks
Dr. Steven Alan Akman treated 116 Medicare patients in 2024, average age 74
CMS counts 116 Medicare patients who saw Dr. Akman in 2024. The largest group is 65 to 74, with 56 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 1.45, where 1.00 is the Medicare average.
Across all payers, Dmand AI patient panel data puts Dr. Akman's median patient age at 69, with 76% women.
Medicare patients, 2024116
Average age74
Average risk score1.45
Dr. Akman's Medicare patients by age, 2024
CMS leaves out age groups with fewer than 11 patients.
Dr. Akman's Medicare patients by sex, 2024
- Women7968%
- Men3732%
Chronic conditions among Dr. Akman's Medicare patients, 2024
- High blood pressure75%
- High cholesterol75%
- Cancer62%
- Arthritis48%
- Diabetes34%
- Anxiety28%
- Chronic kidney disease22%
- Depression22%
Share of Medicare patients with each condition. A patient can have several.
Dr. Akman's patients across all payers
Dmand AI patient panel data covers Medicare, Medicaid and commercial patients.
Patient panel by age, all payers
Median age 69
Patient panel by sex, all payers
- Women76%
- Men23%
Sources: Dmand AI Patient Panel Data; and Medicare Physician & Other Practitioners - by Provider (CMS), 2024 data
Dr. Steven Alan Akman wrote 549 Medicare Part D claims in 2024
In 2024, Dr. Akman wrote 549 Medicare Part D claims for 111 patients. 76% of them were for generic drugs. CMS names the drug for 296 of them, across 14 drugs with 11 or more claims each, at $501,688 in total drug cost. In 2023, CMS named 366 claims across 21 drugs.
Part D claims, 2024549
Drugs named by CMS14
Total drug cost$501,688
Part D patients111
Dr. Akman's Part D claims by kind of drug, 2024
- Generic419 claims76%
- Brand-name130 claims24%
Dr. Akman's most prescribed drugs by claims, 2024
CMS names a drug when it has 11 or more claims. Share is of the claims for drugs CMS names.
Drug classes CMS tracks in Dr. Akman's Part D claims, 2024
- Opioids7%38 of 549 claims
- Antibiotics2%13 of 549 claims
Share of all Part D claims for each drug class CMS reports on. Classes with no claims are left out.
Part D claims for drugs CMS names, 2023 to 2024
- 2023
- 2024
- Claims for drugs CMS names
- 2023: 3662024: 29619%
Drugs named by CMS: 14 in 2024, 21 in 2023.
Sources: Medicare Part D Prescribers - by Provider and Drug (CMS), 2024 data, released May 6, 2026; and Medicare Part D Prescribers - by Provider (CMS), 2024 data
Dr. Steven Alan Akman offers telehealth to Medicare patients
Dr. Akman accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Akman as offering telehealth.
- Accepts Medicare assignment
- Yes
- Offers telehealth
- Yes
Source: Doctors and Clinicians National Downloadable File (CMS)
For MedTech and pharma teams
Find hematologists and oncologists like Dr. Akman by procedure volume and prescribing
Filter 7.4M+ HCPs by Medicare procedures, Part D drugs and Open Payments history, then reach them with verified contacts in one login.
Dr. Steven Alan Akman has 17 publications on record
Dmand AI links 17 papers to Dr. Akman, published from 2011 to 2017. 2011 was the busiest year, with 6. The most frequent topics are Breast Neoplasms, DEAD-box RNA Helicases and DNA. Dr. Akman has published most often in Nucleic Acids Res. Dr. Akman's most frequent co-authors are Edward Allen Levine, MD and John A. Olson, MD.
Papers17
Years published2011 to 2017
Dr. Akman's papers by year, 2011 to 2017
Topics Dr. Akman writes about most
- Breast Neoplasms
- DEAD-box RNA Helicases
- DNA
- G-Quadruplexes
- Cell Line
- Cell Line, Tumor
- Cell Proliferation
- Cell Transformation, Neoplastic
Dr. Akman's most frequent co-authors
Recent publications by Dr. Akman
PLoS Comput Biol
Adaptation, PhysiologicalBreastCell Transformation, Neoplastic
Base SequenceBinding SitesCircular Dichroism
Antineoplastic AgentsBreast NeoplasmsCell Line, Tumor
Biomarkers, TumorBreast NeoplasmsCell Line, Tumor
See who Dr. Akman researches with
Physician Network Discovery turns co-authorship, shared hospitals and shared groups into a map of who Dr. Akman works with, so you can find a warm path to the right hematologists and oncologists.
Sources: PubMed (National Library of Medicine); and Dmand AI Research Linkage
Dr. Steven Alan Akman has worked on 10 clinical trials
Dmand AI links Dr. Akman to 10 clinical trials, 5 of them phase 3 studies. 10 are still active or recruiting. Conditions studied include Melanoma, Nevi and Melanomas and Breast Neoplasms. National Cancer Institute (NCI) sponsors the most, 9.
Clinical trials with Dr. Akman by phase
- NonePhase 1: no trials
- 3Phase 2: 3 trials
- 1Phase 2/3: 1 trial
- 5Phase 3: 5 trials
- NonePhase 4: no trials
Conditions in Dr. Akman's trials
- Melanoma
- Nevi and Melanomas
- Breast Neoplasms
- Carcinoma, Intraductal, Noninfiltrating
- Carcinoma, Non-Small-Cell Lung
Investigators on the most trials with Dr. Akman
- Mehmet Sitki Copur, MD5 shared trials
- Ruby Anne Deveras, MD5 shared trials
- Justin P. Favaro, MD5 shared trials
Recent clinical trials with Dr. Akman
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation (opens in a new tab)
Active, not recruitingPhase 2/3
GliosarcomaGlioblastomaTemozolomideVeliparib
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers (opens in a new tab)
Active, not recruitingPhase 3
IpilimumabNivolumab
Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery (opens in a new tab)
Active, not recruitingPhase 3
MelanomaNevi and MelanomasIpilimumabPembrolizumabRecombinant Interferon Alfa-2b
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma (opens in a new tab)
Active, not recruitingPhase 3
MelanomaNevi and MelanomasIpilimumabNivolumabDabrafenib Mesylate
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (opens in a new tab)
Active, not recruitingPhase 2
Thyroid NeoplasmsThyroid DiseasesAdavosertibAfatinibAfatinib Dimaleate
Sources: Dmand AI Research Linkage; and ClinicalTrials.gov (National Library of Medicine)
Dr. Steven Alan Akman received $6,484 in industry payments from 2016 to 2025
CMS Open Payments shows 36 general payments to Dr. Akman from 14 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 63% of the total. Eli Lilly and Company paid the most, $3,701.
General payments to Dr. Akman by program year, 2016 to 2025
General payments to Dr. Akman by kind, 2016 to 2025
$6.5Kin total
- Consulting fees$4,10063%
- Food and beverage$1,18318%
- Travel and lodging$1,06916%
- Education$1332%
Companies that paid Dr. Akman the most, 2016 to 2025
Share is of all general payments to this clinician.
Source: Open Payments (CMS), 2025 data, released July 7, 2026
Dr. Steven Alan Akman graduated from Albert Einstein College of Medicine of Yeshiva University
Dr. Akman graduated from Albert Einstein College of Medicine of Yeshiva University in 1975.
- Medical school
Source: Dmand AI Professional Profile Data
Sources for Dr. Steven Alan Akman's profile data
| Data on this page | Source |
|---|---|
| NPI, name, sex, specialty and licenses | NPPES NPI Registry (CMS) (opens in a new tab)Dmand AI Professional Profile Data |
| Practice locations and phone | NPPES NPI Registry (CMS) (opens in a new tab)Dmand AI Practice Data |
| Primary practice, affiliations and health system | NPPES NPI Registry (CMS) (opens in a new tab)Dmand AI Practice DataDmand AI Affiliation Data |
| Medicare services and procedure codes | Medicare Physician & Other Practitioners - by Provider and Service (CMS) (opens in a new tab) |
| State medians for the same specialty | Dmand AI Peer Benchmarks |
| Medicare patients and the all-payer patient panel | Dmand AI Patient Panel DataMedicare Physician & Other Practitioners - by Provider (CMS) (opens in a new tab) |
| Part D prescribing | Medicare Part D Prescribers - by Provider and Drug (CMS) (opens in a new tab)Medicare Part D Prescribers - by Provider (CMS) (opens in a new tab) |
| MIPS scores, telehealth, assignment and procedure percentiles | Doctors and Clinicians National Downloadable File (CMS) (opens in a new tab) |
| Publications, topics and co-authors | PubMed (National Library of Medicine) (opens in a new tab)Dmand AI Research Linkage |
| Clinical trials and co-investigators | Dmand AI Research LinkageClinicalTrials.gov (National Library of Medicine) (opens in a new tab) |
| Industry payments | Open Payments (CMS) (opens in a new tab) |
| Training, board certification and memberships | Dmand AI Professional Profile Data |
| EHR at each practice site | Dmand AI Technology Install Data |
| Similar physicians | Dmand AI Affiliation Data |
Data last refreshed October 2026Report an inaccuracyRemove my information
FAQ
Frequently asked questions about Dr. Steven Alan Akman
Spotted something out of date? Email hello@dmand.ai and we will check the record. Contact details live in the free trial.
What is Dr. Steven Alan Akman's NPI number?
Dr. Steven Alan Akman's NPI number is 1396729414. It was assigned on December 1, 2005, and it is active in the NPI Registry.
What kind of doctor is Dr. Steven Alan Akman?
Dr. Steven Alan Akman is a hematologist and oncologist in Mount Pleasant, South Carolina. The primary specialty in the NPI Registry is Hematology & Oncology Physician (taxonomy code 207RH0003X).
Where does Dr. Steven Alan Akman practice?
Dr. Akman practices at 1208 2 Island Ct, Mount Pleasant, SC 29466. Dr. Akman's primary practice is MUSC Physicians in Mount Pleasant, South Carolina. Dmand AI also links Dr. Akman to 2 hospitals, 5 medical groups, 3 group practices and clinics and 1 home health agency.
What is Dr. Steven Alan Akman's office phone number?
The practice phone on file for Dr. Akman is (803) 286-4666.
What is Dr. Steven Alan Akman's medical license number?
Dr. Akman holds South Carolina license 35266, one of the licenses on file in 2 states.
Which states has Dr. Steven Alan Akman been licensed in?
Dmand AI has state licenses on file for Dr. Akman in South Carolina and North Carolina.
Which hospitals is Dr. Steven Alan Akman affiliated with?
Dr. Akman is affiliated with MUSC Health University Medical Center. Dmand AI links Dr. Akman to 2 more hospitals.
What medical group is Dr. Steven Alan Akman part of?
Dr. Akman is linked to MUSC Health. Dmand AI links Dr. Akman to 5 more medical groups.
Does Dr. Steven Alan Akman accept Medicare?
Yes. CMS data shows Dr. Akman billed Medicare for 437 services in 2024, and Dr. Akman accepts Medicare assignment.
Does Dr. Steven Alan Akman offer telehealth?
Yes. The CMS Doctors and Clinicians file lists Dr. Akman as offering telehealth services.
Show 8 more questionsShow fewer questions
How many Medicare patients does Dr. Steven Alan Akman see?
CMS counts 116 Medicare patients who saw Dr. Akman in 2024, with an average age of 74.
What services does Dr. Steven Alan Akman bill to Medicare?
In 2024, Dr. Akman's most billed Medicare services were medicare service (G2211), office visit, established patient (99213) and office visit, established patient (99214).
Where did Dr. Steven Alan Akman go to medical school?
Dr. Akman graduated from Albert Einstein College of Medicine of Yeshiva University in 1975.
What drugs does Dr. Steven Alan Akman prescribe most?
In 2024 Medicare Part D data, Dr. Akman's most prescribed drugs by claims were Letrozole, Ondansetron HCl and Eliquis.
Has Dr. Steven Alan Akman received payments from drug or device companies?
CMS Open Payments shows $6,484 in general payments to Dr. Akman from 14 companies from 2016 to 2025. The largest total came from Eli Lilly and Company.
How long has Dr. Steven Alan Akman been practicing?
Dr. Akman graduated from medical school in 1975, 51 years ago.
Does Dr. Steven Alan Akman do research?
Dmand AI links 17 publications to Dr. Akman, published from 2011 to 2017. Dr. Akman has worked on 10 clinical trials.
Who does Dr. Steven Alan Akman publish with?
Dr. Akman's most frequent co-authors are Edward Allen Levine, MD (1 shared paper) and John A. Olson, MD (1 shared paper).
Selling to hematology and oncology practices?
See hematologists and oncologists in South Carolina by site of care and group
Find the practices, groups and hospitals they work with, and the right people to contact at each.
- 30 days free
- Self-serve
- No credit card